The OraSure HCV Grant Program is a recently announced funding opportunity designed to foster innovative approaches to HCV testing.
The FDA has approved the drug Epclusa to treat adult patients with chronic Hep C both with and without cirrhosis.
The NYS Drug Utilization Review Board voted to eliminate most restrictions on prescribing hepatitis C medications for all Medicaid fee-for-service patients.
To determine the impact of the NYS Hepatitis C Testing Law, the NYSDOH drew from multiple data sources that assessed testing levels in New York before and after the law went into effect.
VOCAL-NY and community leaders will attend the meeting to advocate for unrestricted access to Hepatitis C drug coverage.
The NYS Hep C Coalition has released a 2016 State Budget and Legislative platform.
FDA Expands Daklinza/Sovaldi Approval to Include Treatment of Hep C Genotype 1
Special guests Jason Grebely, Alain Litwin, and Sheila Reynoso presented on best practices to improve Hep C care among people who inject drugs.
The Health Department today released a new report detailing the city’s hepatitis B and C surveillance, research, and programmatic activities in 2014.
The U.S. Food and Drug Administration has approved Zepatier with or without ribavirin for the treatment of chronic Hepatitis C genotypes 1 and 4 infections in adult patients.
